中西医结合治疗绝经后雌激素受体阳性晚期乳腺癌的临床效果

Clinical effect of combination of traditional Chinese and western medicine treating postmenopausal estrogen receptor-positive advanced breast cancer

目的探讨中西医结合治疗绝经后雌激素受体(ER)阳性晚期乳腺癌的临床效果。方法选取2016年3月~2018年10月诊治的我院47例ER阳性且需要行来曲唑激素治疗的绝经后晚期乳腺癌患者作为研究对象,采用随机数字表法将其分为治疗组和对照组,治疗组为23例,对照组为24例。治疗组给予知柏地黄汤配合来曲唑口服,对照组给予来曲唑口服,经过2个疗程(60 d)的治疗,比较两组临床疗效、肿瘤指标变化和不良反应总发生率。结果治疗组和对照组的有效率比较,差异无统计学意义(P>0.05)。两组治疗后糖类抗原15-3(CA15-3)指标均低于两组治疗前,差异有统计学意义(P<0.05);两组治疗后的肿瘤指标CA15-3比较,差异无统计学意义(P>0.05)。治疗组的不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论知柏地黄汤配合来曲唑治疗绝经后ER阳性晚期乳腺癌,近期临床疗效较好,且可以降低来曲唑治疗产生的不良反应,故中西医结合治疗绝经后ER阳性晚期乳腺癌具有较好的使用价值。

Objective To investigate the clinical effect of combination of traditional Chinese and western medicine treating postmenopausal estrogen receptor(ER)-positive advanced breast cancer. Methods A total of 47 patients with postmenopausal ER-positive advanced breast cancer who were positive for ER and required treatment with Letrozole were enrolled in our hospital from March 2016 to October 2018. According to the random number table method, 23 cases were inclucled in the treatment group and 24 cases in the control group. The treatment group was given Zhibai Dihuang Decoction and Letrozole orally, and the control group was given Letrozole orally. After 2 courses(60 days) treatment, the clinical efficacy, tumor index changes and total incidence of adverse reactions were compared between the two groups. Results There was no significant difference in the effective rate between the treatment group and the control group(P>0.05). The levels of carbohydrate antigen 15-3(CA15-3) in two groups were lower than those in each group before treatment, and the differences were statistically significant(P<0.05). Compared the tumor index CA15-3 after treatment in the two groups, the difference was not statistically significant(P>0.05). The total incidence of adverse reactions in the treatment group was lower than that in the control group, and the difference was statistically significant(P<0.05). Conclusion Zhibai Dihuang Decoction combined with Letrozole in the treatment of postmenopausal ER-positive advanced breast cancer has a good clinical effect in the near future, and can reduce the adverse reactions caused by Letrozole treatment. Therefore, the combination of traditional Chinese and western medicine for the treatment of postmenopausal ER-positive advanced breast cancer has a good value.